Key Information
Salary: £31,445 - £41,900 per annum. Commencement on the salary range is subject to comparable skills and experience.
Reporting to: Dr Stephen Pettitt
Duration of Contract: Fixed Term for 12 months in the first instance
Hours per week: 35 hours per week (Full Time)
Location: Chelsea
Closing Date: 8 February 2026
This role will be appointed at either SO or HSO role, depending on the skills and experience of the successful candidate. SO roles are not currently eligible for sponsorship so a candidate appointed at SO level is required to have the right to work in the UK without sponsorship. HSO roles are currently eligible for sponsorship.
Job Details
We are seeking to appoint an enthusiastic, Scientific Officer (SO) or Higher Scientific Officer (HSO) (depending on skills and experience) with experience in in- vivo assays to join the joint Lord & Tutt Precision Oncology laboratory. The main responsibility of this position is to conduct in vivo experiments aimed at optimizing vaccination and other approaches for treating homologous recombination defective cancers.
You will use new in-house developed, state-of-the-art, syngeneic genetically engineered murine tumour models of homologous breast cancer to help with the development of vaccines that target mechanisms of platinum salt and PARP inhibitor resistance (see Pettitt et al Cancer Discov. 2020 Oct;10(10):1475-1488 and Harvey-Jones et al Ann Oncol. 2024 Apr;35(4):364-380).
About You
The successful candidate must have:
* An appropriate degree
* A current Home Office License, including modules A-C (modules 1-4)
Department/Directorate Information
The Precision Oncology Group led by Professors Chris Lord and Andrew Tutt is a multidisciplinary team of cell biologists, geneticists, biochemists, in vivo specialists, bioinformaticians and oncologists. Together we aim to understanding how to exploit the molecular changes that occur in tumours to develop new treatments for cancer or to improve existing treatments. With both UK and international collaborators, we identified the synthetic lethal interaction between BRCA -tumour suppressor genes and PARP inhibitors (Nature 2005), observations that transformed the treatment of breast, ovarian, prostate and pancreatic cancers. In recent years, we have focused on improving the treatment of homologous recombination defective and other cancers by understanding how drug resistance emerges and how this might be targeted. The impact of our work is demonstrated by the number of completed and on-going clinical trials in cancer (some of which we have led) that are based upon synthetic lethal interactions our group identified as well as the number of trials assessing biomarkers of cancer drug sensitivity/resistance that we identified.
The Precision Oncology Group is part of the Division of Breast Cancer Research. The Breast Cancer Now Toby Robins Research Centre, within the Division of Breast Cancer Research at The Institute of Cancer Research began 25 years ago and was the first centre in the UK entirely devoted to breast cancer research. In state-of-the-art laboratory space, with excellent core facilities and is funded through a long-term renewable programme grant from Breast Cancer Now.
What We Offer
* A dynamic and supportive research environment
* Access to state-of-the-art facilities and professional development opportunities
* Collaboration with leading researchers in the field
* Competitive salary and pension
We encourage all applicants to access the job pack attached for more detailed information regarding this role.
About The Institute Of Cancer Research
Why work for us? As a member of staff, you\'ll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.
The Institute of Cancer Research, London, is one of the world\'s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.
Equality, Diversity and Inclusion
At the Institute of Cancer Research, we champion diversity as we believe it fuels innovation and drives impactful research. We welcome applicants from all walks of life, valuing diverse perspectives that enrich our work.
Don\'t let a checklist of qualifications hold you back – if you\'re passionate about the role, we want to hear from you. Your unique experiences and backgrounds contribute to the richness of our team. We are committed to being an equal opportunity for all, regardless of ethnicity, gender, age, sexual orientation, disability, or any other dimension of diversity. Join us in creating an inclusive environment where everyone\'s voice is heard and valued.
#J-18808-Ljbffr